Kiniksa Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Kiniksa Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 23 Dec 2021 | Lorem |
| Humanigen’s and Kiniksa’s anti-GM-CSF antibodies likely to garner a place for nonventilated COVID-19 patients; mixed views on ideal timepoint to measure clinical improvements, experts say | 26 Feb 2021 | Manasi Vaidya;Sean Rai-Roche |
| Anti-GM-CSF antibodies, such as by Roivant, Humanigen and I-Mab, expected to show better effect in COVID-19 than cytokine-specific targets, experts say | 20 May 2020 | Ayisha Sharma;Manasi Vaidya |
| Kiniksa’s Phase IIa KPL-716 still needs to prove MOA in prurigo nodularis as inference from positive pruritus data in atopic dermatitis premature, experts say | 26 Sep 2019 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer